Secondary analysis of ADAPTABLE (14,662 people with ASCVD; 2778 with COPD/asthma): no significant interaction between aspirin 325 vs 81 mg and COPD/asthma on the primary composite outcome (aHR 1.15; P=0.349). Stroke risk was higher with 81 mg in COPD/asthma (aHR 2.41).
Secondary analysisn = 14,662
Mosher et al. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE